Serum β2-microglobulin at HIV-1 seroconversion as a predictor of severe immunodeficiency during 10 years of followup

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue 3, 1996, Pages 262-266

  Phillips, Andrew N ^a,c   Sabin, Caroline A ^a   Elford, Jonathan ^a   Bofill, Margarita ^b   Timms, Anthony ^b   Janossy, George ^b   Lee, Christine A ^b  

^a Research Unit   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c School of Medicine   (United Kingdom)

Author keywords

Age; CD4 Lymphocytes; HIV; Natural history; Seroconversion; 2 Microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN;

ARTICLE; DETERIORATION; DISEASE SEVERITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029961514     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199611010-00008     Document Type: Article

References (43)

1. Hansen PB. Olsen NV. Beta 2-microglobulin in medical disease. Ugeskrift-for Laeger 1989;151(45):2960-2.
2. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serological markers in infection with HIV-1. N Engl J Med 1990;322:166-72.
3. Sabin CA, Phillips AN, Lee CA, et al. Beta-2 microglobulin as a predictor of prognosis in HIV-infected men with haemophilia: a proposed strategy for use in clinical care. Br J Haematol 1994;86(2):366-71.
4. Lacey JN, Forbes MA, Waugh MA, Cooper EH, Hambling MH. Serum beta 2-microglobulin and human immunodeficiency virus infection. AIDS 1987;1(2):123-7.
5. Alcabes P, Selwyn PA, Davenny K, et al. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994;8(1):107-15.
6. Schwartlander B, Bek B, Skarabis H, Koch J, Burkowitz J, Koch MA. Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. The Multicentre Cohort Study Group. AIDS 1993;7(6):813-21.
7. Rezza G, Titti F, Pezzotti P, et al. Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users. J Biol Reg Homeostat Ag 1992;6 (1):15-20.
8. Kramer A, Biggar RJ, Hampl H, et al. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific. Am J Epidemiol 1992; 136(1):71-80.
9. Munoz A, Vlahov D, Solomon L, et al. Prognostic indicators for development of AIDS among intravenous drug users. J Acquir Immune Defic Syndr 1992;5(7):694-700.
10. Lifson AR, Hessol NA, Buchbinder SP, et al. Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection. Lancet 1992;339(8807):1436-40.
11. Chaisson RE, Taylor E, Margolick JB, et al. Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users. J Acquir Immun Defic Syndr 1992;5(5):456-60.
12. Zangerle R, Fuchs D, Reibnegger G, Fritsch P, Wachter H. Markers for disease progression in intravenous drug users infected with HIV-1. AIDS 1991;5(8):985-91.
13. Morfeldt-Manson L, Bottiger B, Nilsson B, von Stedingk LV. Clinical signs and laboratory markers in predicting progression to AIDS in HIV-1 infected patients. Scand J Infect Dis 1991;23(4):443-9.
14. Zabay JM, Sempere JM, Benito JM, et al. Serum beta-2-microglobulin and prediction of progression to AIDS in HIV-infected injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:266-72.
15. Cuthbert RJ, Ludlam CA, Tucker J, et al. Five year prospective study of HIV infection in the Edinburgh haemophiliac cohort. Br Med J 1990;301(6758):956-61.
16. Anderson RE, Lang W, Shiboski S, Royce R, Jewell N, Winkelstein W Jr. Use of beta 2-microglobulin level and CD4 lymphocyte count to predict development of acquired immunodeficiency syndrome in persons with human immunodeficiency virus infection. Arch Intern Med 1990;150(1): 73-7.
17. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J 1988;296(6624):745-50.
18. Phillips AN, Lee CA, Elford J, et al. Serial CD4+ lymphocyte counts and the development of AIDS. Lancet 1991;337: 389-92.
19. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36:S1.
20. Darby SC, Rizza CR, Doll R, et al. Incidence of AIDS and excess of mortality associated with HIV in haemophiliacs in the UK: report on behalf of the directors of haemophilia centres in the UK. Br Med J 1989;298:1064-8.
21. Phillips AN, Lee CA, Elford J, et al. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr 1991;4:970-5.
22. Steel CM, Ludlam CA, Beatson D, et al. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988;1(8596):1185-8.
23. Klein MR, Keet IP, D'Amaro J, et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis 1994;169(6):1244-9.
24. 6/1, AIDS, and death from AIDS? Br Med J 1994;309:1535-7.
25. Pedersen C, Orskov Lindhardt B, Lokke Jensen B, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. Br Med J 1989;299:154-7.
26. Keet IPM, Krijnen P, Koot M, et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993; 7:51-7.
27. Dorrucci M, Rezza G, Vlahov D, et al. Acute retroviral syndrome among injecting drug users: clinical aspects and prognostic value. AIDS 1995;9:597-604.
28. Simmonds P, Beatson D, Cuthbert RJG, et al. Determinants of HIV disease progression: six year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet 1991;338: 1159-63.
29. Cheingsong-Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J, Weber J. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. Br Med J 1991;302(6767): 23-6.
30. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
31. Zangerle R, Fuchs D, Sarcletti M, et al. Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection. Clin Immun Immunopathol 1994;72(3):328-34.
32. Nishanian P, Hofmann B, Wang Y, Jackson AL, Detels R, Fahey JL. Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease. AIDS 1991;5(7):805-12.
33. Nielsen C, Pedersen C, Lundgren JD, Gerstoft J. Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS 1993; 7:1035-40.
34. + cell levels. J Infect Dis 1994;170:775-81.
35. Melmed RN, Taylor JM, Detels R, Bozorgmehri M, Fahey JL. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS. J Acquir Immune Defic Syndr 1989; 2(1):70-6.
36. Schechter MT, Craib KJ, Le TN, et al. Susceptibility to AIDS progression appears early in HIV infection. AIDS 1990;4(3):185-90.
37. Phillips AN, Sabin CA, Elford J, Bofill M, Lee CA, Janossy G. CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up. AIDS 1993;7:975-80.
38. Hofmann B, Wang YX, Cumberland WG, Detels R, Bozorgmehri M, Fahey JL. Serum beta 2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis. AIDS 1990;4(3):207-14.
39. Giorgi JV. HIV pathogenesis and prognostic markers of HIV disease progression: update from the Multicenter AIDS Cohort Study. Abstract S41. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 28-February 1, 1996.
40. Cuthbert TJG, Ludlam CA, Steel CM, Beatson D, Peutherer JF. Immunological studies in HIV seronegative haemophiliacs: relationships to blood therapy. Br J Haematol 1992;80: 364-9.
41. Flegg PJ, Brettle RP, Robertson JR, Clarkson RC, Bird AG. Beta-2-microglobulin levels in drug users: the influence of risk behaviour. AIDS 1991;5:1021-4.
42. Gorter RW, Vranizan KM, Osmond DH, Moss AR. Differences in laboratory values in HIV infection by sex, race and risk group. AIDS 1992;6:1341-7.
43. Chaisson RE, Taylor E, Margolick JB, et al. Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users. J Acquir Immune Defic Syndr 1992;5:456-60.